Despite encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from PBMs. Such companies are typically building https://mohamadxtsw596305.alltdesign.com/company-s-vyndamax-faces-is-encountering-pbm-hurdles-the-review-of-coverage-battles-60761133